Simpson Thacher Expands Secondaries Team With Hire of Ed Ford and Sacha Gofton-Salmond
13.2.2023 19:00:00 EET | Business Wire | Press release
Simpson Thacher & Bartlett LLP announced today that Ed Ford and Sacha Gofton-Salmond will join the Firm as Partners in the London office, where they will focus on secondaries transactions.
“Ed and Sacha are highly regarded in the secondaries space, having built up a market leading practice in recent years and will add depth to our renowned Private Funds and Fund Transactions Practices, further bolstering our ability to advise sponsors and investors on liquidity solutions that provide additional flexibility to address an ever-changing market,” said Alden Millard, Chair of Simpson Thacher’s Executive Committee. “We are thrilled to welcome them to Simpson Thacher.”
“Simpson Thacher has developed a robust presence in the fund transactional space, which was strengthened by the addition of Lauren King in New York in 2021,” said Michael Wolitzer, Head of Simpson Thacher’s Investment Funds Practice. “With the addition of Ed and Sacha, the Firm is further augmenting its capabilities to provide sponsor clients and other industry participants with multidisciplinary secondaries solutions around the globe.”
Ed and Sacha both specialize in advising clients on the structuring and negotiation of highly complex secondary market solutions, ranging from GP- and LP-led secondary transactions to NAV financings, preferred equity financings and other structured secondary transactions. Both lawyers join the Firm from Travers Smith.
“Ed and Sacha are both incredibly talented lawyers that have the versatile experience and commercial creativity that is the hallmark of Simpson Thacher’s Investment Funds Practice,” said Jason Glover, Head of Simpson Thacher’s London office and the Firm’s European Funds team. “We have admired Ed’s and Sacha’s respective success in the secondaries space for some time and believe that their arrival at Simpson Thacher will enhance our existing secondaries transaction platform in London. Such hires mark the latest step in enhancing our private funds offering and solidifying our position as the global investment funds law firm of choice.”
Simpson Thacher’s Fund Transactions Practice advises on the full breadth of secondaries transactions, as well as complex control and minority-stakes transactions involving alternative asset managers and preferred and structured financings for funds, their management companies and other industry participants. Drawing upon the Firm’s more than 40 years of experience in the private equity industry, the global team comprises funds, mergers and acquisitions, finance, tax and other lawyers who provide commercially-driven, comprehensive transactional advice for the world’s most sophisticated sponsors. The multidisciplinary team offers deep market knowledge and creative, tailored advice on transactions, including traditional and synthetic secondaries deals, GP-led restructurings, preferred equity transactions and other liquidity solutions.
ABOUT SIMPSON THACHER
Simpson Thacher & Bartlett LLP (www.simpsonthacher.com) is one of the world’s leading international law firms. The Firm was established in 1884 and has more than 1,000 lawyers. Headquartered in New York with offices in Beijing, Brussels, Hong Kong, Houston, London, Los Angeles, Palo Alto, São Paulo, Tokyo and Washington, D.C., the Firm provides coordinated legal advice and transactional capability to clients around the globe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230213005393/en/
Contact information
Arielle Katz
Communications Manager
mediainquiries@stblaw.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 16:00:00 EEST | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care tea
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 16:00:00 EEST | Press release
Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become operational infrastructure without corresponding security maturity. The report also reveals that AI environments are rapidly becoming more interconnected and business critical. Among organizations adopting AI, 64% now run vector databases, 55
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 16:00:00 EEST | Press release
As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity. The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom